MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  05/17 04:00:01 pm EDT
142.28 USD   +4.42%
05/13MODERNA, INC. Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K/A)
AQ
05/13SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/13KHF Welcomes the African Medicines Agency Treaty Cabinet Approval
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Sector news Other Biotechnology & Medical Research
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
05/16US Stocks Begin Week Mostly Lower as First Manufacturing Data for May Turns Negative
MT
05/16Top Midday Gainers
MT
05/16INSIDER SELL : Seagen
MT
05/16Seagen's President, CEO Clay Siegall Resigns Amid Investigation
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09SECTOR UPDATE : Health Care Stocks Declining Ahead of Monday Close
MT
05/09SECTOR UPDATE : Health Care
MT
05/09Seagen's Shares Drop After CEO Clay Siegall Takes Leave of Absence; Roger Dansey Named ..
MT
05/09Top Midday Decliners
MT
05/09Equities Drop Midday as Economic Growth, Inflation Concerns Mount
MT
05/09Seagen CEO Clay Siegall Takes Leave of Absence; Roger Dansey Named Interim CEO
MT
05/09Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
CI
05/09Seagen Inc. Announces CEO Changes
CI
05/06EuroAPI gains on market debut after spin-off from Sanofi
RE
05/05TikoMed AB and IQVIA Announce Strategic Collaboration for the Development of TikoMed's ..
CI
05/04TRANSCRIPT : IQVIA Holdings Inc. - Special Call
CI
04/29RBC Capital Adjusts Seagen's Price Target to $136 From $132, Maintains Sector Perform R..
MT
04/29IQVIA Holdings Shares Rise Midday Following Piper Upgrade, Target Increase
MT
04/29Oppenheimer Adjusts Seagen Price Target to $160 From $162, Maintains Outperform Rating
MT
04/29Piper Sandler Lifts IQVIA Holdings to Overweight From Neutral, Price Target to $255 Fro..
MT
04/29Investor group led by Derek Hennecke, TJ Higley, Mark Bamforth, Bill Mitchell and other..
CI
04/28Seagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/28TRANSCRIPT : Seagen Inc., Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 20..
CI
04/28Seagen Q1 Loss Widens, Revenue Rises; Maintains 2022 Revenue Outlook
MT
04/28Earnings Flash (SGEN) SEAGEN Posts Q1 Revenue $426.5M, vs. Street Est of $401.7M
MT
04/28Stifel Nicolaus Adjusts Price Target for IQVIA Holdings to $271 From $297, Maintains Bu..
MT
04/28EARNINGS REACTION HISTORY : Seagen Inc, 50.0% Follow-Through Indicator, 6.1% Sensitive
MT
04/28KeyBanc Adjusts IQVIA Holdings' Price Target to $250 from $290, Keeps Overweight Rating
MT
04/27SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Wednesday
MT
04/27TRANSCRIPT : IQVIA Holdings Inc., Q1 2022 Earnings Call, Apr 27, 2022
CI
04/27Iqvia Q1 Adjusted Earnings, Revenue Advance; Company Sets Q2 Guidance
MT
04/27IQVIA Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Earnings Flash (IQV) IQVIA HOLDINGS Reports Q1 Revenue $3.57B, vs. Street Est of $3.538..
MT
04/27Earnings Flash (IQV) IQVIA HOLDINGS Reports Q1 EPS $2.47, vs. Street Est of $2.42
MT
04/27IQVIA Holdings Inc. Provides Earnings Guidance for the Second Quarter and Full Year of ..
CI
04/26TRANSCRIPT : IQVIA Holdings Inc. - Special Call
CI
04/25Lonza Joins Integral Molecular to Offer De-risking of Biotherapeutics
MT
04/25Seagen Q1 Results May Bring Improved 2022 Guidance, Oppenheimer Says
MT
04/25Wells Fargo Downgrades IQVIA Holdings to Equalweight from Overweight, Adjusts Price Tar..
MT
04/25Lonza Signs Licensing Agreement With Luzhu Biotech
MT
04/21AlphaValue/Baader Europe Lifts Price Target on Lonza Group
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on MODERNA, INC.